课题基金 / 基金详情

Identifying Cytoprotective Responses Triggered Following Initial Exposure to Targeted Therapy: Defining Improved Treatment Strategies for Patients with HER-2 Positive Breast Cancer.

Identifying Cytoprotective Responses Triggered Following Initial Exposure to Targeted Therapy: Defining Improved Treatment Strategies for Patients with HER-2 Positive Breast Cancer.
识别初次接触靶向治疗后引发的细胞保护反应：为 HER-2 阳性乳腺癌患者制定改进的治疗策略。
批准号：
202218
负责人：
Bally Marcel B
金额：
$56.4万
依托单位：
B.C. Cancer Research Centre (Vancouver)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2010
资助国家：
加拿大
项目状态：
已结题
起止时间：
2010-03-01 至 2015-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=202218&lang=en
关键词：
Autophagy Breast Cancer Cytoprotective Responses Drug Combinations Trastuzumab Resistance Tumour Models

项目摘要

项目成果

Bally Marcel B的其他基金

相似基金

相关文献

中文摘要
翻译
这个研究项目的重点是开发用于复发性乳腺癌患者的药物组合。更具体地说，相当多的女性患有晚期乳腺癌，表达HER-2，一种与之相关的蛋白质
英文摘要
This research program is focused on the development of drug combinations for use in patients with relapsed breast cancer. More specifically, a significant number of women suffer from advanced breast cancers that express HER-2, a protein that is associated
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Novel Formulation of the Anticancer Drug Candidate CX5461 that Relies on Metal Chemistry and Liposomal Nanotechnology: Development for use in Treatment of Pancreatic Cancer's with BRCA Deficiencies; an Orphan Indication
  • 批准号：
    446517
  • 项目类别：
    Operating Grants
  • 资助金额：
    $55.73万
  • 财政年份：
    2021
  • 负责人：
    Bally Marcel B
  • 依托单位：
    BC Cancer, part of PHSA (Vancouver)
Copper Drug Complexes: Development of a novel class of drugs with significant potential for treatment of platinum insensitive cancers
  • 批准号：
    357858
  • 项目类别：
    Operating Grants
  • 资助金额：
    $35.67万
  • 财政年份：
    2016
  • 负责人：
    Bally Marcel B
  • 依托单位：
    BC Cancer, part of PHSA (Vancouver)
海外基金